Business
DECN adds to Domestic and International Channels for its GenAccord! Product, Inclusive of the EU and Russian Federation, as Company also Schedules Entry of 2nd GenAccord! Product for Multi-Patient Use
DECN adds to Domestic and International Channels for its GenAccord! Product, Inclusive of the EU and Russian Federation, as Company also Schedules Entry of 2nd GenAccord! Product for Multi-Patient Use.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"COMPANY WILL POST INITIAL FORECASTS FOR EACH GENACCORD! PRODUCT JUST AS SOON AS FORECAST AND AVAILABILITY DISCUSSIONS ARE COMPLETED WITH OUR TAIWANESE PARTNER LOS ANGELES, CA / ACCESSWIRE / January 21, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate! Sure and GenUltimate Precis products manufactured for International markets. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system as well as the GenUltimate! 4Pets Test strip and Avantage! meter. Finally the company has completed design and testing of its GenUltimate! TBG ("Dragonfly") diabetes testing system, now coming up on a clinical trial slot in Korea, license to our strategic partner, and FDA 510(k) clearance.In addition, today DECN announces that what began with the initial acceptance of a gesture from our proposed strategic licensing partner to add our GenAccord! meter and test strips to our upcoming agreement, has evolved into much more. The company has completed its market evaluation and targeting and is introducing its FDA 510(k) cleared GenAccord! Enhanced product line into retail, charity and direct distribution markets that serve the uninsured and under-insured diabetics, which number approximately 12 million in the U.S. alone. GenAccord! Enhanced is also going to be independently targeted to the EU, India and Russian Federation markets, which taken together are 70% of the size of the domestic U.S. market.Keith Berman, CEO of DECN commented, "We have completed the packaging for our GenAccord! products and plan introduction in the USA of GenAccord! Enhanced just as soon as product arrives in our warehouses, either in late January or early February 2020. Sometime in early 2Q 2020 we will introduce GenAccord! Enhanced into the EU markets and shortly thereaf...